{"transactions":[{"id":730359,"issuer":{"id":935,"kind":"organization","name":"EXAGEN INC.","symbol":"XGN"},"owners":[{"id":36296,"kind":"person","name":"McKhann Chas","position":1,"cik":"0001631746","reported_name":"McKhann Chas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option(right to buy)","published_at":"2026-06-22T17:11:30.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":37500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date."}],"balance_after":45000,"derivative":{"exercise_price":4.31,"exercise_date":"2026-06-09","expiration_date":"2036-06-08","underlying":"Common Stock","underlying_shares":37500},"source":{"system":"sec-edgar","filing":"0001274737-26-000038","document":"wk-form4_1782148287.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1274737/000127473726000038/wk-form4_1782148287.xml","form_type":"4"}},{"id":805144,"issuer":{"id":7161,"kind":"organization","name":"Envoy Medical, Inc."},"owners":[{"id":36296,"kind":"person","name":"McKhann Chas","position":1,"cik":"0001631746","reported_name":"McKhann Chas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-17T20:32:04.000Z","date":"2026-04-15","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Beginning on 5/15/2026, options to purchase Class A Common Stock will vest pro rata on the 15th of each month for 36 consecutive months."}],"balance_after":100000,"derivative":{"exercise_price":0.72,"expiration_date":"2036-04-15","underlying":"Class A Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000914190-26-000077","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1631746/000091419026000077/form4.xml","form_type":"4"}},{"id":1403274,"issuer":{"id":87417,"kind":"organization","name":"Silk Road Medical Inc","symbol":"SILK"},"owners":[{"id":36296,"kind":"person","name":"McKhann Chas","position":1,"cik":"0001631746","reported_name":"McKhann Chas","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-09-18T20:19:27.000Z","date":"2024-09-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1299042,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, each PSU was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares underlying the PSUs, less applicable taxes and authorized deductions."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001140361-24-041406","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1397702/000114036124041406/form4.xml","form_type":"4"}},{"id":1403273,"issuer":{"id":87417,"kind":"organization","name":"Silk Road Medical Inc","symbol":"SILK"},"owners":[{"id":36296,"kind":"person","name":"McKhann Chas","position":1,"cik":"0001631746","reported_name":"McKhann Chas","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-09-18T20:19:27.000Z","date":"2024-09-17","kind":"grant","planned":false,"acquired":true,"shares":1299042,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Immediately prior to the effective time of the merger, certain RSUs subject to the achievement of performance-based criteria, or PSUs, were deemed achieved and certified by the Issuer's compensation committee."}],"balance_after":1299042,"source":{"system":"sec-edgar","filing":"0001140361-24-041406","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1397702/000114036124041406/form4.xml","form_type":"4"}},{"id":1403272,"issuer":{"id":87417,"kind":"organization","name":"Silk Road Medical Inc","symbol":"SILK"},"owners":[{"id":36296,"kind":"person","name":"McKhann Chas","position":1,"cik":"0001631746","reported_name":"McKhann Chas","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-09-18T20:19:27.000Z","date":"2024-09-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":722396,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported shares are represented by restricted stock units, or RSUs, each of which represents a contingent right to receive one share of Issuer common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Agreement and Plan of Merger dated June 17, 2024, between the Issuer, Boston Scientific Corporation and Seminole Merger Sub, Inc, (the \"Merger Agreement\"), each RSU was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) $27.50 per unit in cash (the \"Merger Consideration\") and (ii) the aggregate number of shares underlying the RSUs, less applicable taxes and authorized deductions."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001140361-24-041406","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1397702/000114036124041406/form4.xml","form_type":"4"}},{"id":1594634,"issuer":{"id":87417,"kind":"organization","name":"Silk Road Medical Inc","symbol":"SILK"},"owners":[{"id":36296,"kind":"person","name":"McKhann Chas","position":1,"cik":"0001631746","reported_name":"McKhann Chas","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-03-05T18:17:31.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":110313,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities are represented by restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of SILK common stock. 25% of the shares shall vest on March 1, 2025 and each one-year anniversary thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":722396,"source":{"system":"sec-edgar","filing":"0001593968-24-000432","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1397702/000159396824000432/primary_01.xml","form_type":"4"}},{"id":1749424,"issuer":{"id":87417,"kind":"organization","name":"Silk Road Medical Inc","symbol":"SILK"},"owners":[{"id":36296,"kind":"person","name":"McKhann Chas","position":1,"cik":"0001631746","reported_name":"McKhann Chas","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-11-03T18:50:17.000Z","date":"2023-11-02","kind":"grant","planned":false,"acquired":true,"shares":612083,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities are represented by restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of SILK common stock. 25% of the shares shall vest on November 2, 2024 and each one-year anniversary thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":612083,"source":{"system":"sec-edgar","filing":"0001593968-23-001398","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1397702/000159396823001398/primary_01.xml","form_type":"4"}},{"id":1927282,"issuer":{"id":114713,"kind":"organization","name":"Apollo Endosurgery, Inc.","symbol":"APEN"},"owners":[{"id":36296,"kind":"person","name":"McKhann Chas","position":1,"cik":"0001631746","reported_name":"McKhann Chas","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-04-04T19:55:55.000Z","date":"2023-04-04","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":459170,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised option to purchase shares of Issuer Common Stock granted under the Issuer's 2006 Stock Option Plan, 2016 Equity Incentive Plan or 2017 Equity Incentive Plan or pursuant to the \"inducement\" grant exception under Rule 5635(c)(4) of the Nasdaq Listing Rules (collectively, the \"Issuer Stock Plans\", and each such option, an \"Issuer Option\"), whether vested or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (1) the amount by which the Merger Consideration exceeds the exercise price per share applicable to such Issuer Option and (2) the aggregate number of shares of Issuer Common Stock issuable upon exercise of such Issuer Option, less applicable taxes and authorized deductions."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised option to purchase shares of Issuer Common Stock granted under the Issuer's 2006 Stock Option Plan, 2016 Equity Incentive Plan or 2017 Equity Incentive Plan or pursuant to the \"inducement\" grant exception under Rule 5635(c)(4) of the Nasdaq Listing Rules (collectively, the \"Issuer Stock Plans\", and each such option, an \"Issuer Option\"), whether vested or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (1) the amount by which the Merger Consideration exceeds the exercise price per share applicable to such Issuer Option and (2) the aggregate number of shares of Issuer Common Stock issuable upon exercise of such Issuer Option, less applicable taxes and authorized deductions."}],"balance_after":0,"derivative":{"exercise_price":3.95,"expiration_date":"2032-06-14","underlying":"Common Stock","underlying_shares":459170},"source":{"system":"sec-edgar","filing":"0001251769-23-000027","document":"wf-form4_168065254258996.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1251769/000125176923000027/wf-form4_168065254258996.xml","form_type":"4"}},{"id":1927281,"issuer":{"id":114713,"kind":"organization","name":"Apollo Endosurgery, Inc.","symbol":"APEN"},"owners":[{"id":36296,"kind":"person","name":"McKhann Chas","position":1,"cik":"0001631746","reported_name":"McKhann Chas","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-04-04T19:55:55.000Z","date":"2023-04-04","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":848733,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised option to purchase shares of Issuer Common Stock granted under the Issuer's 2006 Stock Option Plan, 2016 Equity Incentive Plan or 2017 Equity Incentive Plan or pursuant to the \"inducement\" grant exception under Rule 5635(c)(4) of the Nasdaq Listing Rules (collectively, the \"Issuer Stock Plans\", and each such option, an \"Issuer Option\"), whether vested or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (1) the amount by which the Merger Consideration exceeds the exercise price per share applicable to such Issuer Option and (2) the aggregate number of shares of Issuer Common Stock issuable upon exercise of such Issuer Option, less applicable taxes and authorized deductions."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised option to purchase shares of Issuer Common Stock granted under the Issuer's 2006 Stock Option Plan, 2016 Equity Incentive Plan or 2017 Equity Incentive Plan or pursuant to the \"inducement\" grant exception under Rule 5635(c)(4) of the Nasdaq Listing Rules (collectively, the \"Issuer Stock Plans\", and each such option, an \"Issuer Option\"), whether vested or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (1) the amount by which the Merger Consideration exceeds the exercise price per share applicable to such Issuer Option and (2) the aggregate number of shares of Issuer Common Stock issuable upon exercise of such Issuer Option, less applicable taxes and authorized deductions."}],"balance_after":0,"derivative":{"exercise_price":5.95,"expiration_date":"2031-03-10","underlying":"Common Stock","underlying_shares":848733},"source":{"system":"sec-edgar","filing":"0001251769-23-000027","document":"wf-form4_168065254258996.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1251769/000125176923000027/wf-form4_168065254258996.xml","form_type":"4"}},{"id":1927280,"issuer":{"id":114713,"kind":"organization","name":"Apollo Endosurgery, Inc.","symbol":"APEN"},"owners":[{"id":36296,"kind":"person","name":"McKhann Chas","position":1,"cik":"0001631746","reported_name":"McKhann Chas","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-04-04T19:55:55.000Z","date":"2023-04-04","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":689880,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the disposition of the reporting person's 223,635 shares of Issuer common stock, par value $0.001 per share (\"Issuer Common Stock\"), upon the consummation of the transactions contemplated by the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of November 29, 2022, among the Issuer, Boston Scientific Corporation (\"Parent\") and Textile Merger Sub, Inc., an indirect wholly owned subsidiary of Parent (\"Merger Sub\"), including the consummation of the merger between Issuer and Merger Sub on April 4, 2023 (the \"Merger\"). Pursuant to the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each outstanding share of Issuer Common Stock, was canceled and converted automatically into the right to receive $10.00 in cash, without interest (the \"Merger Consideration\"), less applicable taxes and authorized deductions."},{"field":"shares","element":"transactionShares","label":"F2","text":"Reflects the disposition of the reporting person's 112,607 shares of Issuer RSUs upon the consummation of the Merger. Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit award granted under any Issuer Stock Plan (each, an \"Issuer RSU\"), whether vested but unsettled or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (1) the Merger Consideration and (2) the aggregate number of shares of Issuer Common Stock underlying such Issuer RSU, less applicable taxes and authorized deductions."},{"field":"shares","element":"transactionShares","label":"F3","text":"Reflects the disposition of the reporting person's 353,638 shares of Issuer PSUs upon the consummation of the Merger. Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance restricted stock unit award granted under any Issuer Stock Plan that vests based on achievement of any performance condition and the passage of time (each, an \"Issuer PSU\"), whether vested but unsettled or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (1) the Merger Consideration and (2) the aggregate number of shares of Issuer Common Stock underlying such Issuer PSU (determined as if all performance conditions in the applicable award agreements relating to such Issuer PSU have been satisfied as of immediately prior to the Effective Time), less applicable taxes and authorized deductions."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the disposition of the reporting person's 223,635 shares of Issuer common stock, par value $0.001 per share (\"Issuer Common Stock\"), upon the consummation of the transactions contemplated by the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of November 29, 2022, among the Issuer, Boston Scientific Corporation (\"Parent\") and Textile Merger Sub, Inc., an indirect wholly owned subsidiary of Parent (\"Merger Sub\"), including the consummation of the merger between Issuer and Merger Sub on April 4, 2023 (the \"Merger\"). Pursuant to the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each outstanding share of Issuer Common Stock, was canceled and converted automatically into the right to receive $10.00 in cash, without interest (the \"Merger Consideration\"), less applicable taxes and authorized deductions."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Reflects the disposition of the reporting person's 112,607 shares of Issuer RSUs upon the consummation of the Merger. Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit award granted under any Issuer Stock Plan (each, an \"Issuer RSU\"), whether vested but unsettled or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (1) the Merger Consideration and (2) the aggregate number of shares of Issuer Common Stock underlying such Issuer RSU, less applicable taxes and authorized deductions."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Reflects the disposition of the reporting person's 353,638 shares of Issuer PSUs upon the consummation of the Merger. Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance restricted stock unit award granted under any Issuer Stock Plan that vests based on achievement of any performance condition and the passage of time (each, an \"Issuer PSU\"), whether vested but unsettled or unvested, was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (1) the Merger Consideration and (2) the aggregate number of shares of Issuer Common Stock underlying such Issuer PSU (determined as if all performance conditions in the applicable award agreements relating to such Issuer PSU have been satisfied as of immediately prior to the Effective Time), less applicable taxes and authorized deductions."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001251769-23-000027","document":"wf-form4_168065254258996.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1251769/000125176923000027/wf-form4_168065254258996.xml","form_type":"4"}},{"id":2229669,"issuer":{"id":114713,"kind":"organization","name":"Apollo Endosurgery, Inc.","symbol":"APEN"},"owners":[{"id":36296,"kind":"person","name":"McKhann Chas","position":1,"cik":"0001631746","reported_name":"McKhann Chas","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-16T21:17:40.000Z","date":"2022-06-14","kind":"grant","acquired":true,"shares":459170,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the option shall vest as to 25% on the first anniversary of the grant date and the remainder will vest in equal monthly installments over the following three years, subject to the Reporting Person providing continuous service to the Issuer through each such date. Accelerated vesting may occur in the event of a Change in Control, as that term is defined in the Apollo Endosurgery, Inc. 2017 Equity Incentive Plan."}],"balance_after":459170,"derivative":{"exercise_price":3.95,"expiration_date":"2032-06-14","underlying":"Common Stock","underlying_shares":459170},"source":{"system":"sec-edgar","filing":"0001251769-22-000053","document":"wf-form4_165542864144500.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1251769/000125176922000053/wf-form4_165542864144500.xml","form_type":"4"}},{"id":2229668,"issuer":{"id":114713,"kind":"organization","name":"Apollo Endosurgery, Inc.","symbol":"APEN"},"owners":[{"id":36296,"kind":"person","name":"McKhann Chas","position":1,"cik":"0001631746","reported_name":"McKhann Chas","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-06-16T21:17:40.000Z","date":"2022-06-14","kind":"grant","acquired":true,"shares":112607,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of Restricted Stock Units (\"RSUs\"). Each RSU provides the Reporting Person with a contingent right to receive one share of the Issuer's common stock pursuant to the Issuer's 2017 Equity Incentive Plan (the \"Plan\"). The RSUs vest in equal annual installments over four years commencing on the grant date, subject to the Reporting Person providing continuous service to the Issuer through each such date. Accelerated vesting may occur in the event of a Change in Control, as that term is defined in the Plan."}],"balance_after":689880,"source":{"system":"sec-edgar","filing":"0001251769-22-000053","document":"wf-form4_165542864144500.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1251769/000125176922000053/wf-form4_165542864144500.xml","form_type":"4"}},{"id":2277370,"issuer":{"id":114713,"kind":"organization","name":"Apollo Endosurgery, Inc.","symbol":"APEN"},"owners":[{"id":36296,"kind":"person","name":"McKhann Chas","position":1,"cik":"0001631746","reported_name":"McKhann Chas","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-05-09T16:31:56.000Z","date":"2022-05-05","kind":"tax_withholding","acquired":false,"shares":66553,"price":5.42,"value":360717.26,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction is not a sale of shares by the Reporting Person in the open market. Instead, this represents shares that have been withheld by the Issuer to satisfy the Reporting Person's income tax and withholding obligation in connection with the vesting of the second tranche of previously reported performance-based vesting restricted stock units reported on the Form 4 dated March 12, 2021. This net settlement was approved by the Issuer's compensation committee."}],"balance_after":577273,"source":{"system":"sec-edgar","filing":"0001251769-22-000036","document":"wf-form4_165212829075036.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1251769/000125176922000036/wf-form4_165212829075036.xml","form_type":"4"}},{"id":2594620,"issuer":{"id":114713,"kind":"organization","name":"Apollo Endosurgery, Inc.","symbol":"APEN"},"owners":[{"id":36296,"kind":"person","name":"McKhann Chas","position":1,"cik":"0001631746","reported_name":"McKhann Chas","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-08-20T20:55:06.000Z","date":"2021-08-20","kind":"sale","acquired":false,"shares":21148,"price":7.74,"value":163685.52,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On March 10, 2021, the holder was granted 707,278 performance-based restricted stock units (\"RSUs\"), as previously reported on a Form 4 filed on March 12, 2021. One-quarter (25%) of these RSUs vested upon the Company's achievement of at least $50 million of revenue for the trailing four quarters ended June 30, 2021. Amounts reported represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents weighted average price of shares sold. Prices ranged between $7.59 - $8.09, inclusive. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":643826,"source":{"system":"sec-edgar","filing":"0001251769-21-000107","document":"wf-form4a_162950729073044.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1251769/000125176921000107/wf-form4a_162950729073044.xml","form_type":"4/A","original_submission_date":"2021-08-20"}},{"id":2594619,"issuer":{"id":114713,"kind":"organization","name":"Apollo Endosurgery, Inc.","symbol":"APEN"},"owners":[{"id":36296,"kind":"person","name":"McKhann Chas","position":1,"cik":"0001631746","reported_name":"McKhann Chas","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-08-20T20:55:06.000Z","date":"2021-08-19","kind":"sale","acquired":false,"shares":21148,"price":7.89,"value":166857.72,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On March 10, 2021, the holder was granted 707,278 performance-based restricted stock units (\"RSUs\"), as previously reported on a Form 4 filed on March 12, 2021. One-quarter (25%) of these RSUs vested upon the Company's achievement of at least $50 million of revenue for the trailing four quarters ended June 30, 2021. Amounts reported represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents weighted average price of shares sold. Prices ranged between $7.68 - $8.15, inclusive. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":664974,"source":{"system":"sec-edgar","filing":"0001251769-21-000107","document":"wf-form4a_162950729073044.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1251769/000125176921000107/wf-form4a_162950729073044.xml","form_type":"4/A","original_submission_date":"2021-08-20"}},{"id":2594618,"issuer":{"id":114713,"kind":"organization","name":"Apollo Endosurgery, Inc.","symbol":"APEN"},"owners":[{"id":36296,"kind":"person","name":"McKhann Chas","position":1,"cik":"0001631746","reported_name":"McKhann Chas","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-08-20T20:55:06.000Z","date":"2021-08-18","kind":"sale","acquired":false,"shares":21156,"price":8.21,"value":173690.76,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On March 10, 2021, the holder was granted 707,278 performance-based restricted stock units (\"RSUs\"), as previously reported on a Form 4 filed on March 12, 2021. One-quarter (25%) of these RSUs vested upon the Company's achievement of at least $50 million of revenue for the trailing four quarters ended June 30, 2021. Amounts reported represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents weighted average price of shares sold. Prices ranged between $8.02 - $8.55, inclusive. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":686122,"source":{"system":"sec-edgar","filing":"0001251769-21-000107","document":"wf-form4a_162950729073044.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1251769/000125176921000107/wf-form4a_162950729073044.xml","form_type":"4/A","original_submission_date":"2021-08-20"}},{"id":2594616,"issuer":{"id":114713,"kind":"organization","name":"Apollo Endosurgery, Inc.","symbol":"APEN"},"owners":[{"id":36296,"kind":"person","name":"McKhann Chas","position":1,"cik":"0001631746","reported_name":"McKhann Chas","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-08-20T17:42:43.000Z","date":"2021-08-20","kind":"sale","acquired":false,"shares":21148,"price":7.74,"value":163685.52,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents weighted average price of shares sold. Prices ranged between $7.59 - $8.09, inclusive. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":643826,"source":{"system":"sec-edgar","filing":"0001251769-21-000105","document":"wf-form4_162949574640442.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1251769/000125176921000105/wf-form4_162949574640442.xml","form_type":"4"}},{"id":2594615,"issuer":{"id":114713,"kind":"organization","name":"Apollo Endosurgery, Inc.","symbol":"APEN"},"owners":[{"id":36296,"kind":"person","name":"McKhann Chas","position":1,"cik":"0001631746","reported_name":"McKhann Chas","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-08-20T17:42:43.000Z","date":"2021-08-19","kind":"sale","acquired":false,"shares":21148,"price":7.89,"value":166857.72,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents weighted average price of shares sold. Prices ranged between $7.68 - $8.15, inclusive. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":664974,"source":{"system":"sec-edgar","filing":"0001251769-21-000105","document":"wf-form4_162949574640442.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1251769/000125176921000105/wf-form4_162949574640442.xml","form_type":"4"}},{"id":2594614,"issuer":{"id":114713,"kind":"organization","name":"Apollo Endosurgery, Inc.","symbol":"APEN"},"owners":[{"id":36296,"kind":"person","name":"McKhann Chas","position":1,"cik":"0001631746","reported_name":"McKhann Chas","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-08-20T17:42:43.000Z","date":"2021-08-18","kind":"sale","acquired":false,"shares":21156,"price":8.21,"value":173690.76,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents weighted average price of shares sold. Prices ranged between $8.02 - $8.55, inclusive. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":686122,"source":{"system":"sec-edgar","filing":"0001251769-21-000105","document":"wf-form4_162949574640442.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1251769/000125176921000105/wf-form4_162949574640442.xml","form_type":"4"}},{"id":2791492,"issuer":{"id":114713,"kind":"organization","name":"Apollo Endosurgery, Inc.","symbol":"APEN"},"owners":[{"id":36296,"kind":"person","name":"McKhann Chas","position":1,"cik":"0001631746","reported_name":"McKhann Chas","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-12T17:44:07.000Z","date":"2021-03-10","kind":"grant","acquired":true,"shares":848733,"price":5.95,"value":5049961.35,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F2","text":"The shares underlying the option will vest over a period of four years, with 25% of the shares vesting on the first anniversary of the grant date and the remainder will vest in equal monthly installments over the following three years, subject to the Reporting Person providing continuous service to the Issuer through each such date. Accelerated vesting may occur in the event of a Change in Control, as that term is defined in the Apollo Endosurgery, Inc. 2017 Equity Incentive Plan.  The option, which was granted outside of the 2017 Equity Incentive Plan, was approved by the Issuer's Board of Directors and issued pursuant to the \"inducement\" grant exception under Listing Rule 5635(c)(4) of the Nasdaq Stock Market LLC.  The option will be governed by the terms of the 2017 Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the option will vest over a period of four years, with 25% of the shares vesting on the first anniversary of the grant date and the remainder will vest in equal monthly installments over the following three years, subject to the Reporting Person providing continuous service to the Issuer through each such date. Accelerated vesting may occur in the event of a Change in Control, as that term is defined in the Apollo Endosurgery, Inc. 2017 Equity Incentive Plan.  The option, which was granted outside of the 2017 Equity Incentive Plan, was approved by the Issuer's Board of Directors and issued pursuant to the \"inducement\" grant exception under Listing Rule 5635(c)(4) of the Nasdaq Stock Market LLC.  The option will be governed by the terms of the 2017 Equity Incentive Plan."}],"balance_after":848733,"derivative":{"exercise_price":5.95,"expiration_date":"2031-03-10","underlying":"Common Stock","underlying_shares":848733},"source":{"system":"sec-edgar","filing":"0001251769-21-000032","document":"wf-form4_161558903063463.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1251769/000125176921000032/wf-form4_161558903063463.xml","form_type":"4"}},{"id":2791491,"issuer":{"id":114713,"kind":"organization","name":"Apollo Endosurgery, Inc.","symbol":"APEN"},"owners":[{"id":36296,"kind":"person","name":"McKhann Chas","position":1,"cik":"0001631746","reported_name":"McKhann Chas","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-03-12T17:44:07.000Z","date":"2021-03-10","kind":"grant","acquired":true,"shares":707278,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Represents the grant of Restricted Stock Units (\"RSU\"). Each RSU provides the Reporting Person with a contingent right to receive one share of the Issuer's common stock. One quarter of the RSU grant will vest upon the achievement of revenue for the trailing for the trailing four quarters equal to each of $50 million, $65 million, $80 million and $95 million, subject to the Reporting Person providing continuous service to the Issuer through each such date. Accelerated vesting may occur in the event of a Change in Control, as that term is defined in the Apollo Endosurgery, Inc. 2017 Equity Incentive Plan. The RSU grant, which was granted outside of the 2017 Equity Incentive Plan, was approved by the Issuer's Board of Directors and issued pursuant to the \"inducement\" grant exception under Listing Rule 5635(c)(4) of the Nasdaq Stock Market LLC.  The RSU grant will be governed by the terms of the 2017 Equity Incentive Plan."}],"balance_after":707278,"source":{"system":"sec-edgar","filing":"0001251769-21-000032","document":"wf-form4_161558903063463.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1251769/000125176921000032/wf-form4_161558903063463.xml","form_type":"4"}}]}